AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) went up by 0.39% from its latest closing price when compared to the 1-year high value of $11.20 and move down -119.61%, while AVEO stocks collected -3.95% of loss with the last five trading sessions. Press Release reported on 06/19/20 that AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Worth an Investment?
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) scored price to earnings ratio above its average ratio, recording 196.15 times of increase in earnings at the present.
AVEO Market Performance
AVEO stocks went down by -3.95% for the week, with the monthly drop of -37.50% and a quarterly performance of 42.86%, while its annual performance rate touched -24.24%. The simple moving average for the period of the last 20 days is -22.68% for AVEO stocks with the simple moving average of -20.86% for the last 200 days.
Analysts’ Opinion on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
Many brokerage firms have already submitted their reports for AVEO stocks, with H.C. Wainwright repeating the rating for AVEO shares by setting it to “Buy”. The predicted price for AVEO socks in the upcoming period according to H.C. Wainwright is $1.75 based on the research report published on September 11, 2019.
B. Riley FBR, on the other hand, stated in their research note that they expect to see AVEO stock at the price of $1, previously predicting the value of $5. The rating they have provided for AVEO stocks is “Neutral” according to the report published on February 4, 2019.
H.C. Wainwright gave “ Neutral” rating to AVEO stocks, setting the target price at $1 in the report published on February 1, 2019.
AVEO Stocks -26.30% Far from 50 Day Moving Average
After a stumble in the market that brought AVEO to its low price for the period of the last 52 weeks, AVEO Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -54.46% of loss for the given period.
The stock volatility was left at 8.42%, however, within the period of a single month, the volatility rate increased by 6.92%, while the shares sank at the distance of -33.51% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +26.55% upper at the present time.
In the course of the last 5 trading sessions, AVEO went down by -3.95%, which changed the moving average for the period of 200 days to the total of -44.49% of losses for the stock in comparison to the 20-day moving average settled at $6.47. In addition, AVEO Pharmaceuticals, Inc. saw -18.31% in overturn over the period of a single year with a tendency to cut further losses.
AVEO Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at AVEO Pharmaceuticals, Inc. (AVEO), starting from SANDELL SCOTT D, who bought 1,428,571 shares at the price of $5.25 back on Jun 19. After this action, Rushing now owns 3,952,958 shares of AVEO Pharmaceuticals, Inc., valued at $7,499,998 with the latest closing price.
Sonsini Peter W., the 10% Owner of AVEO Pharmaceuticals, Inc., bought 1,428,571 shares at the value of $5.25 during a trade that took place back on Jun 19, which means that Sonsini Peter W. is holding 3,952,958 shares at the value of $7,499,998 based on the most recent closing price.
AVEO Stock Fundamentals
The current profitability levels are settled at -1.30 for the present operating margin. The net margin for AVEO Pharmaceuticals, Inc. stands at +32.60. Total capital return value is set at -3.34, while invested capital returns managed to touch 195.69. Equity return holds the value 4.30%, with 0.90% for asset returns.
Based on AVEO Pharmaceuticals, Inc. (AVEO), the company’s capital structure generated 106.20 points for debt to equity in total, while total debt to capital is set at the value of 51.50. Total debt to assets is settled at the value of 31.16 with long-term debt to equity ratio rests at -0.21 and long-term debt to capital is 41.74.
The value for Enterprise to Sales is 4.06 with debt to enterprise value settled at -0.70. The receivables turnover for AVEO Pharmaceuticals, Inc. is 12.37 with the total asset turnover at the value of 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.